|
Real-time Estimate
Cboe BZX
10:36:17 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 22.61 USD | +0.76% |
|
-1.83% | - |
| 09-02 | MiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says | MT |
| 09-02 | UBS Raises Price Target on MiniMed to $28 From $25, Keeps Buy Rating | MT |
| Market Cap | 6.31B 5.43B 5.12B 4.67B 8.72B 604B 8.8B 61.01B 23.48B 306B 23.71B 23.19B 972B | P/E 2027 * |
35.1x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 6.02B 5.17B 4.88B 4.45B 8.31B 575B 8.39B 58.14B 22.38B 292B 22.59B 22.1B 927B | EV / Sales 2027 * |
1.75x | EV / Sales 2028 * | 1.54x |
| Free-Float |
10.08% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MMED | Delayed | |
CBOE
| MMED | Real-time | |
|
Tradegate
| B8S | Real-time | |
|
Deutsche Boerse AG
| B8S | Delayed | |
|
Boerse Muenchen
| B8S | Real-time | |
|
Börse Stuttgart
| B8S | Delayed |
Last Transcript : MiniMed Group, Inc.
| 1 day | +0.76% | ||
| 1 week | -1.83% | ||
| Current month | +12.83% | ||
| 1 month | +15.57% | ||
| 3 months | +47.77% | ||
| 6 months | +26.65% |
| 1 week | 22.1 |  | 23.74 |
| 1 month | 18.85 | | 24.43 |
| Current year | 10.65 | | 24.43 |
| 1 year | 10.65 | | 24.43 |
| 3 years | 10.65 | | 24.43 |
| 5 years | 10.65 | | 24.43 |
| 10 years | 10.65 | | 24.43 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/31/26 | Tax | Chief Executive Officer | -31,350 | 0.0112% | ||
| 7/31/26 | Tax | Chief Technology Officer | -8,012 | 0.0029% | ||
| 7/31/26 | Tax | General Counsel | -1,762 | 0.0006% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.76% | -1.83% | - | - | 6.31B | |
| -0.09% | -1.22% | +15.14% | +6.07% | 12.52B | |
| -0.06% | -2.23% | +11.25% | +24.85% | 6.65B | |
| -1.39% | -9.40% | +19.63% | +6.09% | 5.57B | |
| +0.29% | -1.70% | -21.56% | +40.95% | 4.98B | |
| -1.17% | -0.97% | -35.87% | -22.39% | 3.77B | |
| -1.78% | +4.47% | -7.60% | +136.58% | 1.82B | |
| +2.90% | -11.59% | +24.59% | -22.60% | 1.79B | |
| -1.07% | -5.47% | +41.34% | -20.27% | 1.59B | |
| -6.95% | -4.59% | -10.22% | +25.87% | 1.41B | |
| Average | -0.89% | -3.63% | +4.08% | +19.46% | 4.64B | |
| Weighted average by Cap. | -0.41% | -3.79% | +5.30% | +15.13% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 3.44B 2.96B 2.79B 2.54B 4.75B 329B 4.79B 33.21B 12.78B 167B 12.91B 12.62B 529B | 3.72B 3.2B 3.02B 2.75B 5.14B 356B 5.19B 35.95B 13.84B 180B 13.97B 13.66B 573B |
| Net income | 181M 155M 147M 134M 250M 17.28B 252M 1.75B 672M 8.77B 679M 664M 27.85B | 239M 206M 194M 177M 330M 22.85B 333M 2.31B 889M 11.59B 897M 878M 36.81B |
| Net Debt | -297M -255M -241M -220M -410M -28.4B -414M -2.87B -1.1B -14.4B -1.12B -1.09B -45.75B | -600M -516M -487M -444M -829M -57.38B -837M -5.8B -2.23B -29.11B -2.25B -2.2B -92.45B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | US$22.86 | +1.87% | 150,708 |
| 26-09-10 | US$22.44 | -1.41% | 1,652,540 |
| 26-09-09 | US$22.76 | -2.40% | 1,587,725 |
| 26-09-08 | US$23.32 | +0.15% | 1,052,149 |
| 26-09-04 | US$23.29 | -2.33% | 1,719,503 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MMED Stock
Select your edition
All financial news and data tailored to specific country editions
